Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Board expanded from seven to nine directors with Kristine Peterson and Lonnel Coats joining effective October 19, 2026.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded from seven to nine directors with Kristine Peterson and Lonnel Coats joining effective October 19, 2026
- Peterson joins Audit Committee as a Class I director, term expiring at the 2027 annual meeting
- Coats joins Compensation Committee as a Class II director, term expiring at the 2028 annual meeting
- Each received options for 16,600 shares and restricted stock units covering 12,400 shares
- Both directors deemed Nasdaq-independent, with standard cash compensation and indemnification rights
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.